3 Growth Stocks That Could Skyrocket in the Second Half of 2026

Arista, Micron, and Eli Lilly are highlighted as growth leaders into 2H 2026: Arista reported its first $3.0B revenue quarter while sustaining a 45% GAAP operating margin, and Micron surged to $41.5B quarterly revenue (+346% Y/Y) with EPS at $25.11 vs $1.91 last year and expects $51B revenue and $32B diluted EPS guidance at the high end. Lilly grew revenue 48% to $23B on Mounjaro and Zepbound (Mounjaro +91% Y/Y to ~$9.9B; Zepbound +46% to ~$4.9B) and raised full-year 2026 guidance to $85B–$87B. The article frames all three as benefiting from strong secular tailwinds tied to data center/AI workloads and GLP-1 demand, with upside targets ranging up to ~57% (ANET) and ~28% (LLY) plus potential to more than double (MU).

Analysis

This reads less like three independent stock stories and more like three versions of the same market regime: buyers are paying up for credible scarcity, but the payoff profiles differ sharply. ANET is the cleanest near-term beneficiary because networking is a toll booth on AI capex; the risk is not demand collapse but share transfer if hyperscalers standardize more of the stack or if adjacent vendors bundle networking into broader AI infrastructure deals.

MU is the most cyclical of the three and likely the most dangerous to chase outright. HBM strength can support outsized EPS for several quarters, but memory is the archetypal late-cycle trade: once capacity additions and packaging bottlenecks ease, the market can re-rate from scarcity multiple to mid-cycle multiple very quickly. That makes the second-order winners the equipment and packaging ecosystem, while the losers are downstream OEMs and any buyer with limited pricing power if memory costs stay elevated.

LLY is the highest-quality compounding story, but the market is already underwriting years of execution with little room for policy or coverage slippage. The main contrarian point is that investors may be extrapolating gross demand rather than net revenue durability; the real variables are payer restrictions, adherence, and how fast competition narrows convenience or tolerability gaps. In the next 1-3 months, ANET and MU should trade on commentary about spending cadence and supply, while LLY will be more sensitive to reimbursement and capacity updates; over 6-18 months, all three are vulnerable to multiple compression if growth normalizes faster than consensus expects.

Key Decisions for Investors

• Long ANET on pullbacks or via 3-6 month call spreads; pair against CSCO or HPE to isolate AI networking share gain. Falsify if hyperscaler capex guidance slows or Arista gross margin starts trending down from the mid-40s.
• Do not chase MU common after the run; express upside with a call spread or a long MU / short SOXX pair for the next earnings cycle. Risk/reward improves only if HBM lead times stay tight and guidance is revised higher again.
• Maintain LLY as a quality core holding but hedge valuation risk with a LLY / NVO relative-value long if you want exposure to obesity penetration without paying for the entire category. Falsify if Novo closes the supply and efficacy gap faster than expected or payer pullbacks emerge.
• Watch AMAT, LRCX, and KLA as second-order beneficiaries of sustained HBM capex; if MU commentary implies capex duration beyond 2026, these names likely outperform the semiconductor index on a 1-3 month lag.